ULTRAGENYX PHARMACEUTICAL INC. Net Change in Cash
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Net Change in Cash of -$296.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-05
- ULTRAGENYX PHARMACEUTICAL INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$247.00M.
- ULTRAGENYX PHARMACEUTICAL INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$45.00M.
- ULTRAGENYX PHARMACEUTICAL INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$97.03M.
- ULTRAGENYX PHARMACEUTICAL INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$46.07M.
- ULTRAGENYX PHARMACEUTICAL INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $252.00M.
- ULTRAGENYX PHARMACEUTICAL INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$35.00M, a 143.21% decline from fiscal 2023.
- ULTRAGENYX PHARMACEUTICAL INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $81.00M.
- ULTRAGENYX PHARMACEUTICAL INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$171.98M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$296.00M 10-Q · filed 2026-08-05 | ||||||
| 2026-03-31 | -$247.00M 10-Q · filed 2026-05-06 | ||||||
| 2025-12-31 | $252.00M 10-K · filed 2026-02-18 | ||||||
| 2025-09-30 | $30.54M 10-Q · filed 2025-11-05 | ||||||
| 2025-06-30 | $5.00M 10-Q · filed 2026-08-05 | $4.49M 10-Q · filed 2025-08-06 | |||||
| 2025-03-31 | -$45.00M 10-Q · filed 2026-05-06 | -$44.98M 10-Q · filed 2025-05-07 | |||||
| 2024-12-31 | -$35.00M 10-K · filed 2026-02-18 | -$35.24M 10-K · filed 2025-02-19 | |||||
| 2024-09-30 | -$59.19M 10-Q · filed 2025-11-05 | ||||||
| 2024-06-30 | $270.86M 10-Q · filed 2025-08-06 | ||||||
| 2024-03-31 | -$97.03M 10-Q · filed 2025-05-07 | ||||||
| 2023-12-31 | $81.00M 10-K · filed 2026-02-18 | $81.80M 10-K · filed 2024-02-21 | |||||
| 2023-09-30 | -$58.99M 10-Q · filed 2024-11-06 | ||||||
| 2023-06-30 | -$29.93M 10-Q · filed 2024-08-02 | ||||||
| 2023-03-31 | -$46.07M 10-Q · filed 2024-05-03 | ||||||
| 2022-12-31 | -$171.98M 10-K · filed 2025-02-19 | ||||||
| 2022-09-30 | $86.72M 10-Q · filed 2023-11-03 | ||||||
| 2022-06-30 | -$146.87M 10-Q · filed 2023-08-04 | ||||||
| 2022-03-31 | -$153.38M 10-Q · filed 2023-05-05 | ||||||
| 2021-12-31 | -$416.71M 10-K · filed 2024-02-21 | ||||||
| 2021-09-30 | -$516.75M 10-Q · filed 2022-11-03 | ||||||
| 2021-06-30 | -$423.42M 10-Q · filed 2022-07-29 | ||||||
| 2021-03-31 | -$329.89M 10-Q · filed 2022-05-06 | ||||||
| 2020-12-31 | $290.05M 10-K · filed 2023-02-17 | ||||||
| 2020-09-30 | -$235.99M 10-Q · filed 2021-11-03 | ||||||
| 2020-06-30 | -$97.84M 10-Q · filed 2021-08-03 | ||||||
| 2020-03-31 | -$135.28M 10-Q · filed 2021-05-05 | ||||||
| 2019-12-31 | $320.72M 10-K · filed 2022-02-15 | ||||||
| 2019-09-30 | $9.71M 10-Q · filed 2020-10-27 | ||||||
| 2019-06-30 | $18.47M 10-Q · filed 2020-07-30 | ||||||
| 2019-03-31 | $156.45M 10-Q · filed 2020-05-07 | ||||||
| 2018-12-31 | $12.48M 10-K · filed 2021-02-12 | ||||||
| 2018-09-30 | -$17.61M 10-Q · filed 2019-11-06 | ||||||
| 2018-06-30 | $10.29M 10-Q · filed 2019-08-02 | ||||||
| 2018-03-31 | $126.16M 10-Q · filed 2019-05-07 | ||||||
| 2017-12-31 | -$61.57M 10-K · filed 2020-02-14 | ||||||
| 2017-09-30 | -$101.93M 10-Q · filed 2018-11-06 | ||||||
| 2017-06-30 | -$71.59M 10-Q · filed 2018-08-03 | ||||||
| 2017-03-31 | -$2.84M 10-Q · filed 2018-05-08 | ||||||
| 2016-12-31 | $68.75M 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |